Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 03 2020 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
December 2020
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ______________
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ______________
CONTENTS
On December 3, 2020,
Akari Therapeutics, Plc (the “Company”) issued a press release announcing a publication in the American Journal of
Pathology highlighting the potential of nomacopan in the treatment of uveitis and retinal disease.
A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information
in paragraph one of Exhibit 99.1 is hereby incorporated by reference into all effective registration statements filed by the
Company under the Securities Act of 1933.
Exhibit No.
|
99.1
|
Press
release dated December 3, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
Name:
|
Clive Richardson
Chief Executive Officer and Chief Operating Officer
|
Date:
December 3, 2020
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024